HEMK2 and prostate carcinoma: The depletion of KMT9 can inhibit tumor cell proliferation via different mechanisms, for example, by affecting the expression of established cell cycle regulators such as CDK1 or BIRC5, which results in increased G0-G1 arrest and the induction of apoptosis in prostate cancer cells [44].